Needle-Free Vaccine Platform Receives US Patent

February 12, 2008
BioPharm International Editors

A needle-free vaccine platform that elicits a robust immune response against a wide array of viruses and bacteria has been awarded a US patent (#7,314,624 B2), held by the University of Michigan (Ann Arbor, MI).

A needle-free vaccine platform that elicits a robust immune response against a wide array of viruses and bacteria has been awarded a US patent (#7,314,624 B2), held by the University of Michigan (Ann Arbor, MI). NanoBio Corporation (Ann Arbor, MI), a spin-off from the university, has licensed the patent and its associated technology.

The intranasal vaccines, produced using NanoBio’s nanoemulsion platform technology, have elicited a dramatic immune response in animals vaccinated against influenza, anthrax, hepatitis B, and other diseases. In some cases, the immune response is exponentially higher than what is required to provide adequate protection against infection, Nanobio says. Such dramatic levels of immunity would confer significantly higher levels of protection to the vaccinated population at large compared with current injectable vaccines.

NanoBio release